Ask AI
ProCE Banner Events

Share

Tissue Is Not Always the Issue: Expanding Armamentarium of Histology-Agnostic Targeted Therapies

Join us in Chicago or via simulcast for this live, interactive, CME-certified Master Class symposium featuring expert-led presentations and small group patient case discussions on the optimal assessment of histology-agnostic biomarkers and their impact on therapeutic planning across multiple tumor types.

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

Physicians: maximum of 2.00 AMA PRA Category 1 Credits™

This event has expired. No longer available for credits.

Who Should Attend

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with cancer.

Time and location

Friday, June 02, 2023

7:00 PM - 9:00 PM Central Time (CT)

In-personVirtual

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Salon A 5

Agenda

Join us from 6:30-7:00 PM Central Time (CT) for in-person registration or at 7:00 PM CT online when the symposium begins.

  • Welcome and Introduction
  • Histology-Agnostic Biomarker Assessment and Impact on Therapeutic Planning
  • Master Class Interactive Case Discussion
  • Histology-Agnostic Biomarkers and Approved Targeted Therapies: BRAF V600E mutations, RET fusions, NTRK fusions
  • Master Class Interactive Case Discussion
  • Histology-Agnostic Biomarkers and Approved Immunotherapy: TMB-H, MSI-H/dMMR
  • Master Class Interactive Case Discussion
  • Future Directions in Histology-Agnostic Therapies
  • Final Panel Discussion and Audience Question and Answer Session

Location

Venue Name

Hilton Chicago

Address

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Room Name

Salon A 5

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimally integrate histology-agnostic therapies into treatment of eligible patients with cancer. 

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions, mutations, and other targetable genomic alterations in patients with malignant solid tumors
  • Appraise emerging clinical efficacy and safety data supporting the use of histology-agnostic therapies in solid tumors
  • Formulate strategies for integrating histology-agnostic agents into the management of eligible patients with cancer based on biomarker assessment, current evidence as well as expert and guideline recommendations
  • Identify and refer eligible patients with appropriate biomarkers for enrollment in ongoing clinical trials investigating histology-agnostic therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Aadi Bioscience, Bayer HealthCare Pharmaceuticals Inc., and Lilly.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimally integrate histology-agnostic therapies into treatment of eligible patients with cancer. 

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.